T. Rowe Price Associates
NGNE icon

T. Rowe Price Associates’s Neurogene NGNE Stock Holding History

T. Rowe Price Associates’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$280K Buy
+8,896
New +$245K ﹤0.01% 2874
2025
Q1 		– Sell
-123,291
Closed -$2.82M – 3064
2024
Q4 		$2.82M Buy
+123,291
New +$4.59M ﹤0.01% 1483
2022
Q4 		– Sell
-1,015
Closed -$13K – 2963
2022
Q3 		$13K Hold
1,015
– – ﹤0.01% 2931
2022
Q2 		$21K Sell
1,015
-157
-13% -$3.83K ﹤0.01% 2926
2022
Q1 		$44K Buy
1,172
+370
+46% +$21.6K ﹤0.01% 2934
2021
Q4 		$77K Sell
802
-5
-0.6% -$609 ﹤0.01% 2899
2021
Q3 		$117K Sell
807
-970
-55% -$149K ﹤0.01% 2820
2021
Q2 		$328K Buy
1,777
+247
+16% +$54.6K ﹤0.01% 2560
2021
Q1 		$377K Buy
1,530
+526
+52% +$134K ﹤0.01% 2487
2020
Q4 		$283K Buy
1,004
+337
+51% +$82.3K ﹤0.01% 2442
2020
Q3 		$160K Buy
+667
New +$162K ﹤0.01% 2468
2019
Q4 		– Sell
-20,196
Closed -$1.15M – 2545
2019
Q3 		$1.15M Buy
+20,196
New +$1.23M ﹤0.01% 1754
2018
Q3 		– Sell
-67,500
Closed -$3.58M – 2595
2018
Q2 		$3.58M Sell
67,500
-119,250
-64% -$31.1M ﹤0.01% 1481
2018
Q1 		$52.6M Buy
186,750
+17,993
+11% +$4.97M 0.01% 850
2017
Q4 		$39.7M Sell
168,757
-25
-0% -$5.86K 0.01% 955
2017
Q3 		$47.9M Sell
168,782
-35
-0% -$10K 0.01% 861
2017
Q2 		$47.5M Sell
168,817
-35
-0% -$10K 0.01% 842
2017
Q1 		$56.4M Sell
168,852
-1,168
-0.7% -$410K 0.01% 779
2016
Q4 		$56.1M Buy
170,020
+7,052
+4% +$1.9M 0.01% 775
2016
Q3 		$43.5M Buy
+162,968
New +$32.9M 0.01% 856

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

T. Rowe Price Associates's NGNE Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Neurogene (NGNE) in Q2 2026: 8,896 shares worth $280K. The stake represents ﹤0.01% of the portfolio and ranks #2874 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in NGNE as recently as Q4 2024.

T. Rowe Price Associates first reported a position in NGNE in Q3 2016 and has held it in 20 quarters since. The position peaked at $56.4M in Q1 2017. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • T. Rowe Price Associates held 8,896 shares of Neurogene worth $280K as of Q2 2026.
  • Neurogene was a new T. Rowe Price Associates position in Q2 2026.
  • Neurogene made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2874 holding.
  • T. Rowe Price Associates first reported a position in Neurogene in Q3 2016 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Neurogene position peaked at $56.4M in Q1 2017.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.